Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Susan E. Barrowcliffe sold 500 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $22.00, for a total value of $11,000.00. Following the completion of the transaction, the insider now directly owns 500 shares in the company, valued at $11,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Aimmune Therapeutics, Inc. (AIMT) opened at 19.07 on Friday. Aimmune Therapeutics, Inc. has a 12 month low of $14.01 and a 12 month high of $27.31. The stock’s 50 day moving average price is $20.76 and its 200-day moving average price is $20.01. The firm’s market capitalization is $963.70 million.
Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by $0.01. Equities analysts anticipate that Aimmune Therapeutics, Inc. will post ($2.71) EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Franklin Street Advisors Inc. NC purchased a new stake in Aimmune Therapeutics during the first quarter valued at $450,000. State Street Corp raised its stake in Aimmune Therapeutics by 50.5% in the fourth quarter. State Street Corp now owns 576,147 shares of the biotechnology company’s stock valued at $11,782,000 after buying an additional 193,272 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Aimmune Therapeutics during the fourth quarter valued at $2,100,000. Swiss National Bank raised its stake in Aimmune Therapeutics by 17.5% in the first quarter. Swiss National Bank now owns 36,974 shares of the biotechnology company’s stock valued at $803,000 after buying an additional 5,500 shares in the last quarter. Finally, Palo Alto Investors LLC raised its stake in Aimmune Therapeutics by 209.0% in the first quarter. Palo Alto Investors LLC now owns 1,173,498 shares of the biotechnology company’s stock valued at $25,500,000 after buying an additional 793,771 shares in the last quarter. Institutional investors own 69.65% of the company’s stock.
Several equities analysts have issued reports on the company. Zacks Investment Research lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Wedbush reissued an “outperform” rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a research note on Monday, July 24th. BidaskClub lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. ValuEngine raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. Finally, Piper Jaffray Companies set a $38.00 price target on Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, July 27th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $33.00.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.